Clinical Research Focus 31st edition | Cromos Pharma

Clinical Research Focus. 31st Edition

Unleashing Biotech Success: Why Smaller CROs Are the Key to Big Wins

In the fast-paced biotech industry, smaller CROs are gaining traction over their larger counterparts due to their ability to offer personalized services and agile responses to complex challenges. This shift is supported by market trends and the growing preference among biotech firms for more flexible and focused partnerships. The article delves into how companies like Cromos Pharma are not only competing but excelling by providing innovative solutions such as the “No Patients – No Payment” model.

Please follow the link to learn more

FDA Approves Blood Test for Colon Cancer Screening | Cromos Pharma

FDA Approves Blood Test for Colon Cancer Screening

Guardant Health’s blood test for colorectal cancer has received FDA approval, making it the first blood test approved as a primary screening option. This approval also paves the way for Medicare reimbursement. The Shield™ test aims to improve screening rates by offering a convenient, non-invasive alternative to traditional methods.

Please follow the link to learn more.

Expanding Horizons: Syngene-Cromos Pharma Alliance Transforms Clinical Research | Cromos Pharma

Expanding Horizons: Syngene-Cromos Pharma Alliance Transforms Clinical Research

We’re thrilled to announce our strategic alliance with Syngene International Limited! This partnership combines our expertise in offering high-quality execution and global coverage for clinical trials. Together, we simplify patient recruitment across the US, Europe, and India, while providing comprehensive clinical development services. Superior project management ensures seamless execution of global trials and unified project updates.

Please follow the link to learn more.

AstraZeneca's New Calquence Combos Show Promise in CLL, Aiming to Set New Treatment Standards | Cromos Pharma

AstraZeneca’s New Calquence Combos Show Promise in CLL, Aiming to Set New Treatment Standards

AstraZeneca reports promising results from the phase 3 AMPLIFY trial for Calquence in combination therapies for chronic lymphocytic leukemia (CLL). These new regimens, which include fixed-duration treatment options, have shown effectiveness in preventing disease progression, potentially offering a new standard in CLL therapy. The company plans to discuss these results with regulatory authorities, highlighting the potential for these combinations to impact clinical practice significantly.

Please follow the link to learn more.

PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research | Cromos Pharma

PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research

The quality of clinical research is fundamentally supported by strict adherence to international standards and guidelines. In this context, the Project Management Body of Knowledge (PMBoK), ISO 9001, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) standards play a crucial role. These standards are interconnected and complement each other, providing a comprehensive framework for managing projects, ensuring quality, and maintaining regulatory compliance in clinical trials.

Please follow the link to learn more.

Exploring AI's Role in Medical Diagnostics: NIH Study Highlights Potential and Pitfalls | Cromos Pharma

Exploring AI’s Role in Medical Diagnostics: NIH Study Highlights Potential and Pitfalls

A recent NIH study evaluated the performance of an AI model in medical diagnostics, revealing it can accurately diagnose conditions from clinical images but struggles to explain its reasoning. The findings emphasize the need for further development before AI can complement medical decision-making effectively. This insight is crucial for future integration of AI in healthcare, suggesting that while AI shows promise, it retains significant limitations.

Please follow the link to learn more.

Linking Sleep Patterns to Chronic Disease Risks: Insights from Long-term Wearable Device Data | Cromos Pharma

Linking Sleep Patterns to Chronic Disease Risks: Insights from Long-term Wearable Device Data

A comprehensive study utilizing commercial wearable devices has unveiled significant correlations between various sleep patterns and the onset of chronic diseases. This study, part of the All of Us Research Program, leverages long-term data to enhance our understanding of how sleep irregularities, duration, and stages can influence health outcomes, providing a new perspective on preventative health strategies.

Please follow the link to learn more.

Accidental Discovery Boosts CAR T-Cell Therapy Efficacy with 'Keto Diet' Approach | Cromos Pharma

Accidental Discovery Boosts CAR T-Cell Therapy Efficacy with ‘Keto Diet’ Approach

U.S. researchers stumbled upon a novel method to enhance CAR T-cell therapy for cancer by altering nutrient levels during the cells’ growth. By simulating a ‘keto diet’—restricting sugars temporarily—the T cells maintained their stem-like qualities, improving their longevity and cancer-fighting capabilities once reintroduced into the body.

Please follow the link to learn more.

Major Enhancements Set to Transform Clinical Trial Practices with ICH GCP E6 R3 | Cromos Pharma

Major Enhancements Set to Transform Clinical Trial Practices with ICH GCP E6 R3

As the anticipated adoption of ICH GCP E6 (R3) in October 2024 approaches, it’s essential to understand the transformative impact these changes will bring to clinical trials. The shift from the previous R2 to the enhanced R3 version introduces greater flexibility and increased rigor in clinical research, catering to contemporary needs and challenges.

Please follow the link to learn more.

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS